Opioid only

PreclinicalSmall molecule

LLoma Linda University

Opioid only is one of 9 small molecule programs targeting Cleft Palate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cleft PalateActive, not recruiting

Cleft PalatePreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Cleft Palate

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

2 2

Tylenol

KKenvue Brands

Approved

1 3

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Phase 3

1 4

Bupivacaine Hydrochloride

NNorthwestern University

Phase 3

1 5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

—7

Diflucortolone Valerate (nerisona)

LEO Pharma

Preclinical

1 8

Opioid only

LLoma Linda University

Preclinical

1 9

Ofirmev

LLoma Linda University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cleft Palate1 trial

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

Completed·LLoma Linda University·N/A·NCT01500109·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Opioid only. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Opioid only compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Opioid only. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Loma Linda University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLoma Linda University

Opioid only

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cleft Palate1 trial

References

Drug Info

Quick Facts

Related News